Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

BACKGROUNDS: Durability of androgen-deprivation therapy (ADT) for prostate cancer (PC) is limited. Additional selective estrogen receptor modulators (SERMs) may prolong the durability of ADT, because androgen and estrogen signaling drive PC progression. METHODS: Men with treatment-naïve bone metasta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Fujimura, Tetsuya, Takahashi, Satoru, Kume, Haruki, Urano, Tomohiko, Takayama, Kenichi, Yamada, Yuta, Suzuki, Motofumi, Fukuhara, Hiroshi, Nakagawa, Tohru, Inoue, Satoshi, Homma, Yukio
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4630884/
https://ncbi.nlm.nih.gov/pubmed/26526623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1871-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars